TY - JOUR
T1 - Liver Fibrosis Linked to Cognitive Performance in HIV and Hepatitis C
AU - for the Women’s Interagency HIV Study protocol team
AU - Valcour, Victor G.
AU - Rubin, Leah H.
AU - Obasi, Mary U.
AU - Maki, Pauline M.
AU - Peters, Marion G.
AU - Levin, Susanna
AU - Crystal, Howard A.
AU - Young, Mary A.
AU - Mack, Wendy J.
AU - Cohen, Mardge H.
AU - Pierce, Christopher B.
AU - Adimora, Adaora A.
AU - Tien, Phyllis C.
AU - Anastos, Kathryn
AU - Minkoff, Howard
AU - Gustafson, Deborah
AU - Greenblatt, Ruth
AU - Aouizerat, Bradley
AU - Levine, Alexandra
AU - Nowicki, Marek
AU - Gange, Stephen
AU - Golub, Elizabeth
N1 - Funding Information:
A.A.A. received a consultant's fee from ViiV Healthcare in 2014 that was unrelated to the current study. V.G.V.'s work was supported by K24-MH- 098759. This work was supported by a Diversity supplement to the University of California-San Francisco Women's Interagency HIV Study of Northern California (U01AI034989) from the National Institute of Allergy and Infectious Diseases/National Institutes of Health. Dr. Rubin's effortwas supported by K01-MH098798 from National Institutes of Mental Health. The Women's Interagency HIV Study is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI- 34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (UO1-HD-32632). The study is cofunded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (University of California-San Francisco-Clinical and Translational Science Institute Grant Number UL1 RR024131). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© Copyright 2016 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Objective: Because HIV impairs gut barriers to pathogens, HIV-infected adults may be vulnerable to minimal hepatic encephalopathy in the absence of cirrhosis. Background: Cognitive disorders persist in up to one-half of people living with HIV despite access to combination antiretroviral therapy. Minimal hepatic encephalopathy occurs in cirrhotic patients with or without HIV infection and may be associated with inflammation. Design/Methods: A cross-sectional investigation of liver fibrosis severity using the aspartate aminotransferase to platelet ratio index (APRI) and neuropsychological testing performance among women from the Women's Interagency HIV Study. A subset underwent liver transient elastography (FibroScan, n 303). Results: We evaluated 1479 women [mean (SD) age of 46 (9.3) years]: 770 (52%) only HIV infected, 73 (5%) only hepatitis C virus (HCV) infected, 235 (16%) HIV/HCV coinfected, and 401 (27%) uninfected. Of these, 1221 (83%) exhibited APRI ≤0.5 (no or only mild fibrosis), 206 (14%) exhibited APRI >0.5 and ≤1.5 (moderate fibrosis), and 52 (3%) exhibited APRI >1.5 (severe fibrosis). Having moderate or severe fibrosis (APRI >0.5) was associated with worse performance in learning, executive function, memory, psychomotor speed, fluency, and fine motor skills. In these models that adjusted for fibrosis, smaller associations were found for HIV (learning and memory) and HCV (executive functioning and attention). The severity of fibrosis, measured by FibroScan, was associated with worse performance in attention, executive functioning, and fluency. Conclusions: Liver fibrosis had a contribution to cognitive performance independent of HCV and HIV; however, the pattern of neuropsychological deficit associated with fibrosis was not typical of minimal hepatic encephalopathy.
AB - Objective: Because HIV impairs gut barriers to pathogens, HIV-infected adults may be vulnerable to minimal hepatic encephalopathy in the absence of cirrhosis. Background: Cognitive disorders persist in up to one-half of people living with HIV despite access to combination antiretroviral therapy. Minimal hepatic encephalopathy occurs in cirrhotic patients with or without HIV infection and may be associated with inflammation. Design/Methods: A cross-sectional investigation of liver fibrosis severity using the aspartate aminotransferase to platelet ratio index (APRI) and neuropsychological testing performance among women from the Women's Interagency HIV Study. A subset underwent liver transient elastography (FibroScan, n 303). Results: We evaluated 1479 women [mean (SD) age of 46 (9.3) years]: 770 (52%) only HIV infected, 73 (5%) only hepatitis C virus (HCV) infected, 235 (16%) HIV/HCV coinfected, and 401 (27%) uninfected. Of these, 1221 (83%) exhibited APRI ≤0.5 (no or only mild fibrosis), 206 (14%) exhibited APRI >0.5 and ≤1.5 (moderate fibrosis), and 52 (3%) exhibited APRI >1.5 (severe fibrosis). Having moderate or severe fibrosis (APRI >0.5) was associated with worse performance in learning, executive function, memory, psychomotor speed, fluency, and fine motor skills. In these models that adjusted for fibrosis, smaller associations were found for HIV (learning and memory) and HCV (executive functioning and attention). The severity of fibrosis, measured by FibroScan, was associated with worse performance in attention, executive functioning, and fluency. Conclusions: Liver fibrosis had a contribution to cognitive performance independent of HCV and HIV; however, the pattern of neuropsychological deficit associated with fibrosis was not typical of minimal hepatic encephalopathy.
KW - AIDS dementia complex
KW - HIV
KW - cirrhosis
KW - cognition
KW - liver diseases
KW - minimal hepatic encephalopathy
UR - http://www.scopus.com/inward/record.url?scp=84958818464&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958818464&partnerID=8YFLogxK
U2 - 10.1097/QAI.0000000000000957
DO - 10.1097/QAI.0000000000000957
M3 - Article
C2 - 26885801
AN - SCOPUS:84958818464
SN - 1525-4135
VL - 72
SP - 266
EP - 273
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
IS - 3
ER -